ZIOPHARM Oncology Inc (ZIOP) Broker Price Targets For The Coming Week

Josh Kim
December 15, 2016

The Company has 132.74 million shares outstanding and 127.67 million shares were floated in market.

ORBCOMM, Inc. (NASDAQ:ORBC) topped its 52-week high price of $10.98 on Aug 3, 2016 and 52-Week Low Price of $6.51 on Dec 18, 2015. The price to earnings ratio for the company is 0 with a beta of 2.03.

Lets us look over what analysts have to say about performance of the ZIOP. The company beat the analyst EPS Estimate with the difference of $0.25. Covering sell-side analysts have a current quarter earnings per share estimate of $-0.11.

According to 5 analysts, the Average Revenue Estimate for the current Fiscal quarter is $2.51 Billion and the Low Revenue estimate is $2.44 Billion, while the High Revenue estimate is $2.73 Billion.

The stock prices target chart showed high target of 21 kept by analysts at WSJ while the average price target was for 21 as compared to current price of 6.54. The Mean and Low price Targets are $40.21 and $37, respectively. Finally, Stifel Nicolaus reissued a "buy" rating and issued a $45.00 price target on shares of Clovis Oncology in a report on Monday, October 17th.

Best Apps That Should Be On Your iPhone
In this post, we'll show you 5 useful iOS 10 widget apps that should be installed and used on every iPhone. Meanwhile, just two days after its latest beta, Apple has seeded iOS 10.2 beta 7 to developers for testing.

Clovis Oncology (NASDAQ:CLVS) last posted its quarterly earnings data on Thursday, November 3rd. Ziopharm Oncology has a 1-year low of $4.45 and a 1-year high of $14.20. The preferred stock is convertible into 50,551,383 shares of the company's common stock subject to certain beneficial ownership limitations. The volume of the company in the last trading session was 1.02 Million.

06/02/2016 - Raymond James began new coverage on ZIOPHARM Oncology Inc giving the company a "market perform" rating. The stock presently has a PEG Ratio of 0.00. The company's stock is moving with the distance from SMA 50 of 11.56 Percent while the distance from 200-day simple moving average for the stock is 69.62 percent. The stock is now has its Return on Assets (ROA) value of -71.6 Percent. Return on Equity (ROE) stands at -226.4% and Return on Investment (ROI) of 0 percent. The company has an average rating of "Hold" and an average price target of $36.19.

The stock is now showing YTD performance of 6.6 Percent.

Analyst recommendations and estimates are for informational purposes only and should be used along with a number of other factors when considering an investment position. The Stock had a 2.75 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 2.43 and 2 respectively. Finally, Mizuho lifted their price target on shares of Clovis Oncology from $15.00 to $23.00 and gave the company a neutral rating in a research note on Wednesday, August 24th.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it -0.76% to close at $6.54 with the total traded volume of 2.57 Million shares. Boston Partners bought a new position in shares of Clovis Oncology during the second quarter worth approximately $1,540,000. BlackRock Inc. now owns 2,875 shares of the biopharmaceutical company's stock worth $103,000 after buying an additional 318 shares during the last quarter. This consensus estimate is using information from analysts taken into consideration by Thomson Reuters.

Other reports by MyHealthBowl

Discuss This Article

FOLLOW OUR NEWSPAPER